TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02783859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Amoxicillin-clavulanic Acid)
Study: NCT01083472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice(TM) Reconstructive Tissue Matrix
Description: Strattice(TM) TM will be used to support the repair of abdominal wall defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture/suture with absorbable mesh
Description: Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
Study: NCT02774278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
Study: NCT02122523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near-Infrared (NIR) dye Indocyanin Green (ICG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared (NIR) dye Indocyanin Green (ICG)
Study: NCT01312675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.A.F.E.BT
Description: Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
Study: NCT01538407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
Study: NCT00827619

Intervention type: DEVICE
Group type: OTHER
Intervention: Zilver® Flex™ Vascular Stent
Description: Stenting of the Above-the-Knee Femoropopliteal Artery
Study: NCT01339013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic Conserving Device (AnaConDa )
Description: Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
Study: NCT01872936

Intervention type: DRUG
Group type: OTHER
Intervention: Miravirsen

Intervention type: DRUG
Group type: OTHER
Intervention: Miravirsen

Intervention type: DRUG
Group type: OTHER
Intervention: Telaprevir

Intervention type: DRUG
Group type: OTHER
Intervention: Telaprevir

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Study: NCT00491530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin calcium
Description: Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study: NCT01293669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6987
Description: TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
Study: NCT02741531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder filled with saline solution
Description: Patients in this arm will have their bladders filled with 150 cc of saline solution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline solution
Description: Saline solution will be used to partially fill patients' bladders
Study: NCT04268212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bitter melon juice (100 ml)
Description: Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
Study: NCT03072875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAMS-RAS
Study: NCT05581888

Intervention type: DEVICE
Group type: OTHER
Intervention: trifocal intraocular lens
Description: Binocular implantation of two different trifocal intraocular lens in high myopic cataracts

Intervention type: DEVICE
Group type: OTHER
Intervention: trifocal intraocular lens
Description: Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
Study: NCT01366105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. by K.C.I.
Description: Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
Study: NCT00182637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study: NCT01023464

Intervention type: OTHER
Group type: OTHER
Intervention: FID114657
Description: artificial tears

Intervention type: OTHER
Group type: OTHER
Intervention: FID114657
Description: artificial tears

Intervention type: OTHER
Group type: OTHER
Intervention: SootheXP Emollient (Lubricant) Eye Drops
Description: artificial tears

Intervention type: OTHER
Group type: OTHER
Intervention: SootheXP Emollient (Lubricant) Eye Drops
Description: artificial tears
Study: NCT02767245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Thiamine IV 100 mg/day
Study: NCT03889795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin oral pill will be taken daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin oral pill will be taken once daily.
Study: NCT03024632

Intervention type: PROCEDURE
Intervention: Trial of labor
Description: trial of labor after 3 or more previous cesarean deliveries
Study: NCT03052153

Intervention type: OTHER
Intervention: No investigational intervention performed for this study
Description: No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
Study: NCT00754286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Scented Wand
Description: The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wand
Description: Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
Study: NCT02474901

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Live Attenuated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Live Attenuated Influenza Vaccine
Study: NCT01496703

Intervention type: OTHER
Intervention: no intervention, this is an observational retrospective trial
Description: no intervention, this is an observational retrospective trial
Study: NCT04102982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camrelizumab
Description: Patients will be treated with camrelizumab alone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab plus microwave ablation
Description: In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
Study: NCT03169972

Intervention type: BIOLOGICAL
Intervention: ADYNOVATE
Description: Antihemophilic Factor (Recombinant), PEGylated

Intervention type: BIOLOGICAL
Intervention: ADYNOVATE
Description: Antihemophilic Factor (Recombinant), PEGylated
Study: NCT04612127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement consumption and physical exercise
Description: The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement consumption and physical exercise
Description: The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week.
Study: NCT03708770

Intervention type: DEVICE
Group type: OTHER
Intervention: everlinQ endoAVF System
Study: NCT03517007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-Out Protocol
Description: Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
Study: NCT02856373

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
Study: NCT01184118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 220 mcg 2 puffs BID
Description: The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
Study: NCT01374464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: 4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: 4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: 4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: 4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine
Study: NCT00800384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Description: Implantable defibrillator to detect and terminate ventricular arrhythmias

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable defibrillator
Description: Implantable defibrillator to detect and terminate ventricular arrhythmias
Study: NCT01351558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee muscle strengthening exercises
Description: Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity strengthening exercises
Description: Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular fitness exercises
Description: Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
Study: NCT03321032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stents
Description: Cre8 Evo coronary stent system (CID, Saluggia, Italy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolinx Polymer-based zotarolimus-eluting stents
Description: Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
Study: NCT03329872

Intervention type: OTHER
Intervention: Data collection
Description: data collection about symptoms without any specific clinical or biological intervention
Study: NCT05362539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: diagnostic cystoscopy for detection of any bladder lesions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography
Description: Computed tomography for patients to exclude bladder lesions

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA hypermethylation assay
Description: DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine cytology
Description: voided urine cytology for all patients
Study: NCT00853047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules; orally 3 times daily.
Study: NCT03014869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
Study: NCT00820638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myomo e100
Description: use of the myomo e100 in home
Study: NCT00853047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules; orally 3 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules; orally 3 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules; orally 3 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules; orally 3 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching telotristat etiprate capsules; orally 3 times daily.
Study: NCT01905683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (16-20 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
Study: NCT03600727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used to offer intraoperative sedation for patients in Propofol group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
Study: NCT03338686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft (FGG)
Description: Free Gingival Graft (FGG) was performed on all study sites in this arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft followed by Laser Gingivoplasty
Description: Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
Study: NCT00908661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
Description: Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
Study: NCT00294567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium channel blockers (amlodipine, azelnidipine)
Description: Drug: amlodipine Drug: azelnidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium channel blockers (amlodipine, azelnidipine)
Description: Drug: amlodipine Drug: azelnidipine
Study: NCT01932580

Intervention type: DRUG
Group type: OTHER
Intervention: FLOT (5-fluorouracil, oxaliplatin, docetaxel)
Description: Administration of FLOT chemotherapy before and after surgery
Study: NCT02151604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation of hyperpolarized xenon gas
Description: The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.